Clinical Trial Update: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating BL-B01D1 in combination with a PD-1 monoclonal antibody for unresectable locally advanced or recurrent metastatic triple-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• BL-B01D1
• PD-1 monoclonal antibody

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING